公开(公告)号：US10662184B2

公开(公告)日：2020-05-26

申请号：US16289212

申请日：2019-02-28

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Christophe Andrez ,  Kristen Nicole Burford ,  Sultan Chowdhury ,  Charles Jay Cohen ,  Christoph Martin Dehnhardt ,  Robert Joseph Devita ,  James Roy Empfield ,  Thilo Focken ,  Michael Edward Grimwood ,  Syed Abid Hasan ,  James Philip Johnson, Jr. ,  Alla Yurevna Zenova

IPC: C07D417/12 ,  C07D417/14 ,  C07D401/12 ,  C07D401/14 ,  C07D451/06 ,  C07D403/12 ,  C07D213/76 ,  C07D237/20 ,  C07D239/69 ,  C07D413/12 ,  C07D261/16 ,  C07D493/10 ,  C07D277/52 ,  C07D285/08

Abstract: This invention is directed to methods of preparing benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

公开(公告)号：US20200087239A1

公开(公告)日：2020-03-19

申请号：US16685335

申请日：2019-11-15

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Ivan William HEMEON ,  Brian Salvatore SAFINA ,  Daniel SUTHERLIN

IPC: C07C62/38 ,  C07C69/757 ,  C07C62/34 ,  C07C229/48 ,  C07D211/22 ,  C07C317/44 ,  C07C323/61 ,  A61P25/00 ,  A61P29/00 ,  A61P17/04 ,  C07C313/04

Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RAA, n, ring A, X1, L, m, X2, R2, R3, R4, R5, X, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US10513526B2

公开(公告)日：2019-12-24

申请号：US16156718

申请日：2018-10-10

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Ronen Ben-David ,  Stephen Bierlmaier ,  Ralph Curtis Haltiwanger ,  Alexandr Jegorov ,  Raeann Ruiyun Wu ,  Mehran Yazdanian

IPC: C07D491/20 ,  A61K31/407

Abstract: The present invention provides solid state forms of certain spiro-oxindole compounds, such as funapide and the racemic mixture of funapide and its corresponding (R) enantiomer, pharmaceutical compositions comprising the solid state forms and processes for preparing the solid state forms and the pharmaceutical compositions.

公开(公告)号：US20180105504A1

公开(公告)日：2018-04-19

申请号：US15799771

申请日：2017-10-31

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Daniel SUTHERLIN ,  Steven MCKERRALL ,  Michael Scott WILSON ,  Kwong Wah LAI ,  Philippe BERGERON ,  Birong ZHANG

IPC: C07D277/52 ,  C07D239/69 ,  C07D285/08 ,  C07D417/12 ,  C07D213/76 ,  C07D401/12 ,  C07D403/12 ,  C07D261/16

CPC classification number: C07D277/52 ,  A61K31/427 ,  A61P19/02 ,  A61P29/00 ,  C07D213/76 ,  C07D239/69 ,  C07D261/16 ,  C07D285/08 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12

Abstract: The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1-Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US20170095449A1

公开(公告)日：2017-04-06

申请号：US15290676

申请日：2016-10-11

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Conrad Stewart Winters ,  Meidong Yang ,  Haigang Chen

IPC: A61K31/407 ,  A61K47/14 ,  A61K47/10 ,  A61K9/00 ,  A61K9/06

CPC classification number: A61K31/407 ,  A61K9/0014 ,  A61K9/06 ,  A61K47/10 ,  A61K47/14

Abstract: This invention is directed to pharmaceutical compositions for topical administration to a mammal, wherein the pharmaceutical compositions comprise a spiro-oxindole compound, as an enantiomer, a racemate or a non-racemic mixture, or a pharmaceutically acceptable salt thereof. These pharmaceutical compositions are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions.

公开(公告)号：US20170066777A1

公开(公告)日：2017-03-09

申请号：US15265549

申请日：2016-09-14

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Shaoyi Sun ,  Jianmin Fu ,  Sultan Chowdhury ,  Ivan William Hemeon ,  Michael Edward Grimwood ,  Tarek Suhayl Mansour

IPC: C07D491/20 ,  C07D405/14 ,  C07D405/04 ,  C07D405/06

CPC classification number: C07D491/20 ,  C07D209/34 ,  C07D405/04 ,  C07D405/06 ,  C07D405/10 ,  C07D405/14 ,  C07D491/107

Abstract: This invention is directed to asymmetric syntheses of certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Abstract translation: 本发明涉及某些螺 - 羟吲哚衍生物的不对称合成，其可用于治疗和/或预防钠通道介导的疾病或病症，例如疼痛。

公开(公告)号：US09550775B2

公开(公告)日：2017-01-24

申请号：US14772735

申请日：2014-03-14

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Paul Robert Bichler ,  Sultan Chowdhury ,  Shannon Marie Decker ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Ivan William Hemeon ,  Brian Safina ,  Tao Sheng ,  Shaoyi Sun ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: C07D401/14 ,  A61K31/437 ,  C07D471/04 ,  C07D519/00 ,  C07D471/08

CPC classification number: C07D471/04 ,  C07D471/08 ,  C07D519/00

Abstract: The invention provides compounds having the general formula: [insert formula (I)] (I) and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Abstract translation: 本发明提供具有以下通式的化合物：[插入式（I）]（I）及其药学上可接受的盐，其中变量RA，下标n，环A，X2，L，下标m，X1，R1，R2，R3 ，R4和RN具有本文所述的含义，以及含有这些化合物的组合物和使用这些化合物和组合物的方法。

公开(公告)号：US09481677B2

公开(公告)日：2016-11-01

申请号：US14355549

申请日：2012-10-30

Applicant: XENON PHARMACEUTICALS INC.

Inventor： Shifeng Liu ,  Thilo Focken ,  Navjot Chahal ,  Zaihui Zhang ,  Renata Marcella Oballa ,  Julia Fonarev

IPC: C07D487/04 ,  C07D417/12 ,  C07D471/04 ,  C07D473/00 ,  C07D417/14 ,  C07D403/12

CPC classification number: C07D487/04 ,  C07D403/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D473/00

Abstract: This invention is directed to biaryl ether sulfonamides, or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Abstract translation: 本发明涉及用于治疗和/或预防钠通道介导的疾病或病症例如疼痛的联芳基醚磺酰胺或其药学上可接受的盐，溶剂合物或前药。

公开(公告)号：US20160009710A1

公开(公告)日：2016-01-14

申请号：US14772735

申请日：2014-03-14

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Paul Robert BICHLER ,  Sultan CHOWDHURY ,  Shannon Marie DECKER ,  Christopher Martin DEHNHARDT ,  Thilo FOCKEN ,  Michael Edward GRIMWOOD ,  Ivan William HEMEON ,  Brian SAFINA ,  Tao SHENG ,  Shaoyi SUN ,  Michael Scott WILSON ,  Alla Yurevna ZENOVA

IPC: C07D471/04

CPC classification number: C07D471/04 ,  C07D471/08 ,  C07D519/00

Abstract: The invention provides compounds having the general formula: [insert formula (I)] (I) and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Abstract translation: 本发明提供具有以下通式的化合物：[插入式（I）]（I）及其药学上可接受的盐，其中变量RA，下标n，环A，X2，L，下标m，X1，R1，R2，R3 ，R4和RN具有本文所述的含义，以及含有这些化合物的组合物和使用这些化合物和组合物的方法。

公开(公告)号：US20160009667A1

公开(公告)日：2016-01-14

申请号：US14772726

申请日：2014-03-14

Applicant: Sultan CHOWDHURY ,  Christoph Martin DEHNHARDT ,  Shaoyi SUN ,  GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Chien-An CHEN ,  Sultan CHOWDHURY ,  Christoph Martin DEHNHARDT ,  Shaoyi SUN

IPC: C07D261/20 ,  C07D413/12

CPC classification number: C07D261/20 ,  C07D413/12

Abstract: The invention provides compounds having the general formula (I): and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Abstract translation: 本发明提供具有通式（I）的化合物及其药学上可接受的盐，其中变量RA，下标n，环A，X2，L，下标m，X1，R1，R2，R3，R4和RN具有 含有本文所述的含义，以及含有这些化合物的组合物和使用这些化合物和组合物的方法。